Sarah M. Hartz

Sarah M. Hartz

Auto-generated profile, based on publicly available information

Sarah M. Hartz

Washington University School of Medicine

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2012 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CLCathy C Laurie
Cathy C Laurie
CLCecelia A Laurie
Cecelia A Laurie
KRKenneth Rice
Kenneth Rice
KDKimberly F Doheny
Kimberly F Doheny
LZLeila R Zelnick
Leila R Zelnick
BWBruce S Weir
Bruce S Weir
Cathy Laurie and colleagues detect mosaicism for large chromosomal abnormalities in peripheral blood in a subset of healthy individuals. They show that the frequency of such events increases with age and is associated with elevated risk of developing a subsequent hematological cancer. We detected clonal mosaicism for large chromosomal anomalies (duplications, deletions and uniparental disomy) using SNP microarray data from over 50,000 subjects recruited for genome-wide association studies. This detection method requires a relatively high frequency of cells with the same abnormal karyotype (>5–10%; presumably of clonal origin) in the presence of normal cells. The frequency of detectable clonal mosaicism in peripheral blood is low (<0.5%) from birth until 50 years of age, after which it rapidly rises to 2–3% in the elderly. Many of the mosaic anomalies are characteristic of those found in hematological cancers and identify common deleted regions with genes previously associated with these cancers. Although only 3% of subjects with detectable clonal mosaicism had any record of hematological cancer before DNA sampling, those without a previous diagnosis have an estimated tenfold higher risk of a subsequent hematological cancer (95% confidence interval = 6–18).

6 August 2018 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
RGRichard Grucza
Richard Grucza
KSKenneth J. Sher
Kenneth J. Sher
WKWilliam C. Kerr
William C. Kerr
MKMelissa J. Krauss
Melissa J. Krauss
CLCamillia K. Lui
Camillia K. Lui
LBLaura J. Bierut
Laura J. Bierut

1 March 2014 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
SHSarah M. Hartz
Sarah M. Hartz
CPCarlos N. Pato
Carlos N. Pato
HMHelena Medeiros
Helena Medeiros
PCPatricia Cavazos-Rehg
Patricia Cavazos-Rehg
JSJanet L. Sobell
Janet L. Sobell
FCfor the Genomic Psychiatry Cohort Consortium
for the Genomic Psychiatry Cohort Consortium
Individuals with severe mental illness die approximately 25 years earlier than the general population, and the cause of this early death is largely owing to medical illness that can be attributed to substance use disorders.1-3 For example, although suicide and injury are more common among individuals with chronic mental illness, 60% of premature deaths in persons with schizophrenia are due to medical conditions including heart and lung disease and infectious illness caused by modifiable risk factors such as smoking, alcohol consumption, and intravenous drug use.1 In addition to early mortality, the severity and prognosis of the primary mental illness are worsened in the context of substance dependence.4,5

26 February 2020 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
RPRenato Polimanti
Renato Polimanti
RWRaymond K. Walters
Raymond K. Walters
EJEmma C. Johnson
Emma C. Johnson
JMJeanette N. McClintick
Jeanette N. McClintick
AAAmy E. Adkins
Amy E. Adkins
JGJoel Gelernter
Joel Gelernter

2 September 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EOEmily Olfson
Emily Olfson
CCCatherine E. Cottrell
Catherine E. Cottrell
NDNicholas O. Davidson
Nicholas O. Davidson
CGChristina Gurnett
Christina Gurnett
JHJonathan W. Heusel
Jonathan W. Heusel
LBLaura J. Bierut
Laura J. Bierut
The American College of Medical Genetics and Genomics (ACMG) recommends that clinical sequencing laboratories return secondary findings in 56 genes associated with medically actionable conditions. Our goal was to apply a systematic, stringent approach consistent with clinical standards to estimate the prevalence of pathogenic variants associated with such conditions using a diverse sequencing reference sample. Candidate variants in the 56 ACMG genes were selected from Phase 1 of the 1000 Genomes dataset, which contains sequencing information on 1,092 unrelated individuals from across the world. These variants were filtered using the Human Gene Mutation Database (HGMD) Professional version and defined parameters, appraised through literature review, and examined by a clinical laboratory specialist and expert physician. Over 70,000 genetic variants were extracted from the 56 genes, and filtering identified 237 variants annotated as disease causing by HGMD Professional. Literature review and expert evaluation determined that 7 of these variants were pathogenic or likely pathogenic. Furthermore, 5 additional truncating variants not listed as disease causing in HGMD Professional were identified as likely pathogenic. These 12 secondary findings are associated with diseases that could inform medical follow-up, including cancer predisposition syndromes, cardiac conditions, and familial hypercholesterolemia. The majority of the identified medically actionable findings were in individuals from the European (5/379) and Americas (4/181) ancestry groups, with fewer findings in Asian (2/286) and African (1/246) ancestry groups. Our results suggest that medically relevant secondary findings can be identified in approximately 1% (12/1092) of individuals in a diverse reference sample. As clinical sequencing laboratories continue to implement the ACMG recommendations, our results highlight that at least a small number of potentially important secondary findings can be selected for return. Our results also confirm that understudied populations will not reap proportionate benefits of genomic medicine, highlighting the need for continued research efforts on genetic diseases in these populations.

15 March 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PLPeng Lin
Peng Lin
SHSarah M. Hartz
Sarah M. Hartz
ZZZhehao Zhang
Zhehao Zhang
SSScott F. Saccone
Scott F. Saccone
JWJia Wang
Jia Wang
GCGeneva For The Coga Collaborators Cogend Collaborators
Geneva For The Coga Collaborators Cogend Collaborators
As the amount of data from genome wide association studies grows dramatically, many interesting scientific questions require imputation to combine or expand datasets. However, there are two situations for which imputation has been problematic: (1) polymorphisms with low minor allele frequency (MAF), and (2) datasets where subjects are genotyped on different platforms. Traditional measures of imputation cannot effectively address these problems. We introduce a new statistic, the imputation quality score (IQS). In order to differentiate between well-imputed and poorly-imputed single nucleotide polymorphisms (SNPs), IQS adjusts the concordance between imputed and genotyped SNPs for chance. We first evaluated IQS in relation to minor allele frequency. Using a sample of subjects genotyped on the Illumina 1 M array, we extracted those SNPs that were also on the Illumina 550 K array and imputed them to the full set of the 1 M SNPs. As expected, the average IQS value drops dramatically with a decrease in minor allele frequency, indicating that IQS appropriately adjusts for minor allele frequency. We then evaluated whether IQS can filter poorly-imputed SNPs in situations where cases and controls are genotyped on different platforms. Randomly dividing the data into “cases” and “controls”, we extracted the Illumina 550 K SNPs from the cases and imputed the remaining Illumina 1 M SNPs. The initial Q-Q plot for the test of association between cases and controls was grossly distorted (λ = 1.15) and had 4016 false positives, reflecting imputation error. After filtering out SNPs with IQS0.99 demonstrating that a database of IQS values from common imputations could be used as an effective filter to combine data genotyped on different platforms. IQS effectively differentiates well-imputed and poorly-imputed SNPs. It is particularly useful for SNPs with low minor allele frequency and when datasets are genotyped on different platforms.